Audit of the first > 7500 noninvasive prenatal aneuploidy tests in a Swiss genetics center

Arch Gynecol Obstet. 2022 May;305(5):1185-1192. doi: 10.1007/s00404-021-06203-7. Epub 2021 Sep 17.

Abstract

Objectives: Noninvasive prenatal testing (NIPT) is actually the most accurate method of screening for fetal chromosomal aberration (FCA). We used pregnancy outcome record to evaluate a complete data set of single nucleotide polymorphism-based test results performed by a Swiss genetics center.

Materials and methods: The Panorama® test assesses the risk of fetal trisomies (21, 18 and 13), gonosomal aneuploidy (GAN), triploidy or vanishing twins (VTT) and five different microdeletions (MD). We evaluated all 7549 test results meeting legal and quality requirements taken in women with nondonor singleton pregnancies between April 2013 and September 2016 classifying them as high or low risk. Follow-up ended after 9 months, data collection 7 months later.

Results: The Panorama® test provided conclusive results in 96.1% of cases, detecting 153 FCA: T21 n = 76, T18 n = 19, T13 n = 15, GAN n = 19, VTT n = 13 and MD n = 11 (overall prevalence 2.0%). Pregnancy outcome record was available for 68.6% of conclusive laboratory results, including 2.0% high-risk cases. In this cohort the Panorama® test exhibited 99.90% sensitivity for each trisomy; specificity was 99.90% for T21, 99.98% for T18 and 99.94% for T13. False positive rate was 0.10% for T21, 0.02% for T18 and 0.06% for T13.

Conclusion: SNP-based testing by a Swiss genetics center confirms the expected accuracy of NIPT in FCA detection.

Keywords: Aneuploidy screening; Cell-free DNA; Chromosomal aberration; Microdeletion; SNP-based NIPT.

MeSH terms

  • Aneuploidy
  • Cell-Free Nucleic Acids*
  • Chromosome Disorders* / diagnosis
  • Female
  • Humans
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Prenatal Diagnosis / methods
  • Switzerland
  • Trisomy
  • Trisomy 13 Syndrome / diagnosis
  • Trisomy 18 Syndrome / diagnosis

Substances

  • Cell-Free Nucleic Acids